XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Balance Sheet Details (Tables)
3 Months Ended
Mar. 31, 2024
Balance Sheet Details [Abstract]  
Schedule of Inventories Inventories primarily relate to ENTADFI product and consisted of the following as of March 31, 2024, and December 31, 2023:
   March 31,
2024
   December 31,
2023
 
Raw materials  $135,198   $139,208 
Work-in-process   256,148    194,805 
Finished goods   4,966    30,039 
Total  $396,312   $364,052 
Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of March 31, 2024, and December 31, 2023:
   March 31,
2024
   December 31,
2023
 
Prepaid insurance  $796,282   $122,004 
Prepaid regulatory fees   208,367    312,551 
Prepaid research and development   89,195    89,195 
Prepaid professional fees   
    70,708 
Prepaid other   87,879    175,695 
Total  $1,181,723   $770,153 
Schedule of Intangible Assets Intangible assets, which were recorded during the year ended December 31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note 5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of March 31, 2024, and December 31, 2023:
   Balance at December 31,
2023
   Impairment   Foreign
Currency
Translation
   Balance at March 31,
2024
 
Gross basis:                
Trade name  $9,312,739   $
   $(625,714)  $8,687,025 
Product rights for developed technology   14,182,157    (2,276,194)   (731,386)   11,174,577 
Customer relationships   1,952,803    
    (131,207)   1,821,596 
Total intangible assets, gross  $25,447,699   $(2,276,194)  $(1,488,307)  $21,683,198 

 

   Balance at December 31,
2023
   Amortization   Foreign
Currency
Translation
   Balance at March 31,
2024
 
Accumulated amortization:                
Product rights for developed technology  $(31,213)  $(170,929)  $7,430   $(194,712)
Customer relationships   (5,599)   (30,664)   1,332    (34,931)
Total intangible assets, accumulated amortization  $(36,812)  $(201,593)  $8,762   $(229,643)
Intangible assets, net  $25,410,887             $21,453,555 
Schedule of Annual Amortization Expense Future annual amortization expense related to the Company’s finite lived intangible assets is as follows as of March 31, 2024:
Years ending December 31,    
2024  $598,786 
2025   968,457 
2026   968,457 
2027   968,457 
2028   968,457 
Thereafter   8,293,916 
Total  $12,766,530 

 

Schedule of Goodwill Goodwill consisted of the following as of March 31, 2024 and December 31, 2023:
Balance as of December 31, 2023  $55,676,142 
Impairment loss   (5,192,000)
Foreign currency translation   (3,740,823)
Balance as of March 31, 2024  $46,743,319 
Schedule of Accrued Expenses Accrued expenses consisted of the following as of March 31, 2024, and December 31, 2023:
   March 31,
2024
   December 31,
2023
 
Accrued compensation  $568,559   $487,579 
Accrued research and development   463,506    616,707 
Accrued professional fees   445,569    550,415 
Other accrued expenses   264,593    265,849 
Accrued implementation fees   93,787    93,787 
Accrued franchise taxes   50,000    60,530 
Accrued interest – related party   50,000    
 
Accrued deferred offering costs   
    125,000 
Total  $1,936,014   $2,199,867